Survodutide
A dual GLP-1/glucagon receptor agonist under investigation for obesity and liver-fat reduction via combined appetite suppression and lipid metabolism effects.
Research status: Phase 3 trials in progress.
This page is a research-orientation summary, not a dosing guide. For anything beyond general background, read the primary literature or talk to a qualified clinician — specifics like amount, frequency, or administration aren't something we publish here.
Related in Weight Loss